Compass Therapeutics (CMPX) Q2 2025: 17-Month Survival Surpasses 20%, Delaying Key OS Readout

2025-08-11 | By EarningsIQ Research

Compass Therapeutics’ Q2 update revealed a pivotal shift: the median survival in its lead biliary tract cancer trial now exceeds 20% at 17 months, delaying the anticipated overall survival (OS) analysis into Q1 2026. This lower-than-expected event rate signals potential clinical impact for Tevesimig, while two deep partial responses in early CTX8371 cohorts point to next-generation checkpoint promise. With $101 million in cash extending runway into 2027, attention turns to regulatory milestones and data catalysts across a robust pipeline.

Summary

• Delayed Event Accumulation Signals Clinical Impact: Fewer deaths in the lead trial suggest Tevesimig may extend survival.
• Bispecific Pipeline Shows Early Efficacy: CTX8371 delivered deep partial responses in heavily pretreated cancer patients.
• Milestone-Rich 18 Months Ahead: Multiple clinical readouts and regulatory filings set to define Compass’s trajectory.

Performance Analysis

Compass Therapeutics’ Q2 was defined by clinical, not commercial, inflection. The company’s lead program, Tevesimig, a DLL4 VEGFA bispecific antibody, is in a randomized, fully-enrolled phase 2 trial for advanced biliary tract cancer. The trial’s primary endpoint—overall response rate (ORR)—was already met with a 17.1% ORR, nearly tripling the control arm and achieving statistical significance. However, the most strategic update is the delayed timing of secondary endpoint analyses: fewer deaths than projected mean the required 80% OS event threshold for progression-free survival (PFS) and OS will not be reached until Q1 2026, several months later than previously anticipated.

This delay, driven by unexpectedly high survival rates, hints at a material clinical benefit from Tevesimig. At over 17 months median follow-up, pooled survival exceeds 20%, compared to less than 10% at 18 months in historical controls (ABC06). Crossover from control to Tevesimig is permitted, with about half of control patients eventually receiving the drug, and statistical adjustments (RPSFT method) will be used for OS analysis. Beyond Tevesimig, CTX8371 (PD-1, PD-L1 bispecific) showed two deep partial responses in early dose escalation, including a >90% tumor reduction in a triple negative breast cancer patient post-checkpoint inhibitor therapy. Preclinical data for CTX10726 (PD-1 VEGF bispecific) demonstrated superior tumor control versus class leaders, with IND filing on track for Q4.

• Event-Driven Delay: OS and PFS analyses for Tevesimig now expected Q1 2026 due to lower-than-expected death rate.
• Response Rate Outperformance: Tevesimig’s ORR nearly tripled control in a challenging second-line setting.
• Early-Phase Pipeline Momentum: CTX8371 delivered clinically meaningful responses without dose-limiting toxicities in heavily pretreated patients.

With $101 million in cash, Compass maintains a multi-year runway to pursue these milestones, providing operational stability as the company approaches high-value regulatory and clinical catalysts.

Executive Commentary

Strategic Positioning

1. Tevesimig: Pivotal Survival Data and Regulatory Path

Tevesimig’s unexpectedly strong survival signals could position it as a new standard in second-line biliary tract cancer, a setting with historically poor outcomes. The trial’s hierarchical endpoint structure and crossover-adjusted OS analysis are designed to withstand regulatory scrutiny. Fast track status is in place, and management is preparing for robust FDA engagement in 2026, with a possible BLA (Biologics License Application) submission targeted for mid-2026. The company is also planning a basket study in DLL4-positive tumors to expand Tevesimig’s addressable market.

2. CTX8371: Next-Generation Checkpoint Inhibition

CTX8371’s early efficacy in heavily pretreated solid tumors, including deep partial responses in non-small cell lung cancer and triple negative breast cancer, supports Compass’s thesis that dual PD-1/PD-L1 blockade can deliver synergy beyond conventional checkpoint inhibitors. No dose-limiting toxicities have been observed to date, and expansion cohorts in these two tumor types will initiate later this year. The mechanism—conversion of PD-1 positive T cells to negative—differentiates the asset within a crowded immuno-oncology landscape.

3. CTX10726: Preclinical Differentiation and Manufacturing Readiness

CTX10726, a PD-1 VEGF bispecific, has shown preclinical superiority to both class leader Ivanesimab and pembrolizumab in tumor models, demonstrating Compass’s internal discovery strength. The company has already achieved commercial-level yields in manufacturing, de-risking future scale-up. IND filing is on track for Q4 2025, with first-in-human data expected next year.

4. Cash Runway and Capital Allocation Discipline

With $101 million in cash, Compass projects operational runway into 2027, providing a buffer to execute on multiple late-stage and early-stage milestones without near-term financing risk. This positions the company to negotiate partnerships or licensing from a position of strength as pivotal data emerges.

Key Considerations

The quarter’s updates highlight Compass’s transition from early-stage biotech to a late-clinical-stage contender, but also raise the bar for execution and regulatory navigation as pivotal data approaches.

Key Considerations:

• Survival Data Interpretation: The delayed OS readout, while positive, introduces uncertainty around final magnitude of benefit and regulatory timelines.
• Crossover Adjustment Complexity: About half of control patients crossed over to Tevesimig, requiring sophisticated statistical methods to isolate drug effect.
• Pipeline Breadth vs. Focus: Multiple bispecific assets in the clinic and preclinical stages offer diversification, but also demand operational discipline to avoid resource dilution.
• Regulatory and Market Access: FDA engagement and clear endpoint wins will be critical for Tevesimig’s path to approval and commercial uptake.
• Biomarker Strategy: Companion diagnostics and patient selection (e.g., DLL4, PD-L1) remain under-addressed areas that could impact trial success and market positioning.

Risks

Compass faces several material risks as it advances its pipeline: The pivotal survival benefit for Tevesimig remains unconfirmed until the Q1 2026 OS analysis, and regulatory approval is subject to both efficacy magnitude and statistical rigor, especially with crossover adjustments. Competitive pressure in immuno-oncology is intense, and any safety signals or weaker-than-expected data in expansion cohorts could erode investor confidence. Finally, operational execution across multiple programs and regulatory filings will test management’s bandwidth and manufacturing capabilities.

Forward Outlook

For Q3 and Q4 2025, Compass guided to:

• Initiation of CTX8371 expansion cohorts in non-small cell lung and triple negative breast cancer
• IND filing for CTX10726 in Q4 2025

For full-year 2025 and into 2026, management maintained its milestone roadmap:

• Tevesimig PFS and OS readout in Q1 2026, followed by FDA engagement and potential BLA filing mid-2026
• Multiple clinical readouts and data presentations across the pipeline

Management emphasized that cash runway extends into 2027 and that priority will be placed on regulatory progress and clinical data generation in the coming quarters.

• Q1 2026 OS/PFS analysis for Tevesimig is a defining catalyst
• Early CTX8371 expansion data will shape next-generation checkpoint positioning

Takeaways

Compass’s Q2 update marks a strategic inflection, with survival data in biliary tract cancer hinting at real clinical impact and the bispecific pipeline showing signs of differentiation. The next 12-18 months will be defined by regulatory and clinical milestones that will determine whether Compass can convert scientific promise into durable value.

• Survival Signal Sets High Expectations: Delayed OS events in the pivotal trial suggest Tevesimig’s effect may be material, but the final magnitude and regulatory acceptance remain to be seen.
• Pipeline Assets Are Progressing: CTX8371 and CTX10726 are advancing on schedule, with early efficacy and manufacturing readiness supporting future optionality.
• Execution and Data Delivery Remain the Watchpoints: Investors should focus on the Q1 2026 survival readout, expansion cohort data, and the company’s ability to manage multiple programs without dilution of focus.

Conclusion

Compass Therapeutics enters a catalyst-rich period, with delayed survival events in its lead trial raising hopes for clinical impact and next-generation bispecifics showing early differentiation. Execution against this dense milestone calendar will be critical to unlocking value and validating Compass’s multi-asset approach.

Industry Read-Through

The delayed OS event accumulation in Compass’s pivotal biliary tract cancer trial highlights a broader trend in oncology: as therapies improve, traditional event-driven endpoints can become moving targets, complicating trial timelines and regulatory strategy. Bispecific antibody innovation continues to accelerate, with Compass demonstrating both clinical and preclinical differentiation against established and emerging competitors. Manufacturing readiness and biomarker-driven patient selection are increasingly decisive in both regulatory and commercial success, with lessons for other immuno-oncology developers and investors tracking the next wave of checkpoint and multi-targeted therapeutics.

CMPX Healthcare Biotechnology Immuno-oncology Bispecifics Clinical trials Regulatory